# A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

> **NCT05358379** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 330 (estimated)

## Conditions studied

- Solid Tumor, Adult Lymphoma

## Interventions

- **DRUG:** CYC140

## Key facts

- **NCT ID:** NCT05358379
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-14
- **Primary completion:** 2025-08
- **Final completion:** 2025-11
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05358379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05358379, "A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05358379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*